TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1 . A method for treating a patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, said method comprising administering to the patient h(Gly2)GLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient.
2 . A method as defined in claim 2 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 5 to 500 μg/kg.
3 . A method as defined in claim 3 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
4 . A method as defined in claim 1 , wherein the h(Gly2)GLP-2 is administered by subcutaneous injection.
5 . A method as defined in claim 5 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
6 . A method as defined in claim 1 , wherein the reduction on dependency is a decrease in the amount of parenteral nutrition received by the patient.
7 . A method as defined in claim 1 , wherein the reduction on dependency is a decrease in days or weeks of parenteral nutrition received by the patient.
8 . A method as defined in claim 1 , wherein the patient is an adult.
9 . A method for treating a patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, comprising administering to the patient h(Gly2)GLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient; wherein the GLP-2 receptor agonist is administered daily at a dose of from 30 to 150 μg/kg by subcutaneous injection into the abdomen, thigh, or arm.
10 . A method as defined in claim 9 , wherein the reduction on dependency is a decrease in the amount of parenteral nutrition received by the patient or a decrease in days or weeks of parenteral nutrition received by the patient.
11 . A method as defined in claim 9 , wherein the patient is an adult.
12 . A method for treating an adult patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, comprising administering to the patient h(Gly2)GLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient.
13 . A method as defined in claim 12 , wherein the h(Gly2)GLP-2 is administered daily at a dose of from 30 to 150 μg/kg.
14 . A method as defined in claim 12 , wherein the h(Gly2)GLP-2 is administered by subcutaneous injection.
15 . A method as defined in claim 12 , wherein the reduction on dependency is a decrease in the amount of parenteral nutrition received by the patient or a decrease in days or weeks of parenteral nutrition received by the patient.
16 . A method as defined in claim 1 , wherein said regimen comprises administration of said h(Gly2)GLP-2 over a period of at least 21 days.
17 . A method as defined in claim 9 , wherein said regimen comprises administration of said h(Gly2)GLP-2 over a period of at least 21 days.
18 . A method as defined in claim 12 , wherein said regimen comprises administration of said h(Gly2)GLP-2 over a period of at least 21 days.
19 . A method as defined in claim 1 , wherein said patient is an adult and the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
20 . A method as defined in claim 12 , wherein said patient is an adult and the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.